This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Multiple sclerosis (MS)	Lymphocyte antigen 75 (LY75; DEC-205); proteolipid protein 1 (PLP1)	<p>A study in mice suggests that DEC-205-targeted delivery of a PLP1 fragment could help treat MS. In a mouse model of experimental autoimmune encephalitis (EAE), a PLP1 fragment fused to a DEC-205-targeting mAb decreased MS symptoms compared with the same fragment fused to a control mAb, suggesting that the DEC-205-PLP1 fusion protein increased immunological tolerance. Next steps could include evaluating combination with multiple DEC-205-targeted peptide fragments in the EAE mouse model.</p> <p>SciBX 3(39); doi:10.1038/scibx.2010.1171 Published online Oct. 7, 2010</p>	Patent and licensing status unavailable	<p>Stern, J.N.H. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Sept. 20, 2010; doi:10.1073/pnas.1010263107 Contact: Jack L. Strominger, Harvard Medical School, Boston, Mass. e-mail: jlstrom@fas.harvard.edu Contact: Joel N.H. Stern, same affiliation as above e-mail: jsstern@fas.harvard.edu Contact: Karsten Kretschmer, Dresden Technical University, Dresden, Germany e-mail: karsten.kretschmer@crt-dresden.de</p>